The heart in Friedreich's Ataxia: Basic findings and clinical implications

Progress in Pediatric Cardiology

Volumn 31, Issue 2, 2011, Pages 103-109

  Payne, R Mark ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ataxia; Cardiomyopathy; Genetic; Heart; Mitochondria; Neuropathy

Indexed keywords

DEFERIPRONE; FRATAXIN; IDEBENONE;

ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CARDIOMYOPATHY; CLINICAL FEATURE; DISEASE MODEL; FRATAXIN GENE; FRIEDREICH ATAXIA; GENE; HEART FAILURE; HUMAN; INCIDENCE; IRON CHELATION; NEWBORN SCREENING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR;

EID: 79955468608     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2011.02.007     Document Type: Article

References (71)

1. Harding A.E. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981, 104:589-620.
2. Reddy P.L., Grewal R.P. Friedreich's ataxia: a clinical and genetic analysis. Clin Neurol Neurosurg 2007, 109:200-202.
3. De Biase I., Rasmussen A., Endres D., et al. Progressive GAA expansions in dorsal root ganglia of Friedreich's ataxia patients. Ann Neurol 2007, 61:55-60.
4. Patel P.I., Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am J Hum Genet 2001, 69:15.
5. Friedreich N. Ueber degenerative Atrophie der spinalen Hinterstränge. Virchows Arch 1863, 26:391-419.
6. Boyer S.H., Chisholm A.W., McKusick V.A. Cardiac aspects of Friedreich's ataxia. Circulation 1962, 25:493-505.
7. Schols L., Amoiridis G., Przuntek H., Frank G., Epplen J.T., Epplen C. Friedreich's ataxia: revision of the phenotype according to molecular genetics. Brain 1997, 120:2131-2140.
8. Filla A., De Michele G., Marconi R., et al. Prevalence of hereditary ataxias and spastic paraplegias in Molise, a region of Italy. J Neurol 1992, 239:351-353.
9. Romeo G., Menozzi P., Ferlini A., et al. Incidence of Friedreich ataxia in Italy estimated from consanguineous marriages. Am J Hum Genet 1983, 35:523-529.
10. Skre H. Friedreich's ataxia in Western Norway. Clin Genet 1975, 7:287-298.
11. Epplen C., Epplen J.T., Frank G., Miterski B., Santos E.J., Schols L. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997, 99:834-836.
12. Pandolfo M. Friedreich ataxia. Arch Neurol 2008, 65:1296-1303.
13. Gacy A.M., Goellner G.M., Spiro C., et al. GAA instability in Friedreich's Ataxia shares a common, DNA-directed and intraallelic mechanism with other trinucleotide diseases. Mol Cell 1998, 1:583-593.
14. Sakamoto N., Ohshima K., Montermini L., Pandolfo M., Wells R.D. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 2001, 276:27171-27177.
15. Herman D., Jenssen K., Burnett R., Soragni E., Perlman S.L., Gottesfeld J.M. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006, 2:551-558.
16. Puccio H., Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 2000, 9:887.
17. Huang M.L., Becker E.M., Whitnall M., Rahmanto Y.S., Ponka P., Richardson D.R. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci USA 2009, 106:16381-16386.
18. Cavadini P., Adamec J., Taroni F., Gakh O., Isaya G. Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates. J Biol Chem 2000, 275:41469.
19. Condo I., Ventura N., Malisan F., Rufini A., Tomassini B., Testi R. In vivo maturation of human frataxin. Hum Mol Genet 2007, 16:1534-1540.
20. Schmucker S., Argentini M., Carelle-Calmels N., Martelli A., Puccio H. The in vivo mitochondrial two-step maturation of human frataxin. Hum Mol Genet 2008, 17:3521-3531.
21. O'Neill H.A., Gakh O., Isaya G. Supramolecular assemblies of human frataxin are formed via subunit-subunit interactions mediated by a non-conserved amino-terminal region. J Mol Biol 2005, 345:433-439.
22. O'Neill H.A., Gakh O., Park S., et al. Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry 2005, 44:537.
23. Schagerlof U., Elmlund H., Gakh O., et al. Structural basis of the iron storage function of frataxin from single-particle reconstruction of the iron-loaded oligomer. Biochemistry 2008, 47:4948-4954.
24. Nichol H., Gakh O., O'Neill H.A., Pickering I.J., Isaya G., George G.N. Structure of frataxin iron cores: an X-ray absorption spectroscopic study. Biochemistry 2003, 42:5971.
25. Zhang Y., Lyver E.R., Knight S.A., Pain D., Lesuisse E., Dancis A. Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria. J Biol Chem 2006, 281:22493-22502.
26. Shan Y., Napoli E., Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum Mol Genet 2007, 16:929-941.
27. Yoon T., Cowan J.A. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem 2004, 279:25943-25946.
28. Martelli A., Wattenhofer-Donze M., Schmucker S., Bouvet S., Reutenauer L., Puccio H. Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet 2007, 16:2651-2658.
29. Rotig A., de L.P., Chretien D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997, 17:215.
30. Lodi R., Cooper J.M., Bradley J.L., et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA 1999, 96:11492.
31. Lodi R., Rajagopalan B., Blamire A.M., et al. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc Res 2001, 52:111-119.
32. Pandolfo M. Iron and Friedreich ataxia. J Neural Transm 2006, 143-146.
33. Schulz J.B., Dehmer T., Schols L., et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000, 55:1719.
34. Puccio H., Simon D., Cossee M., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001, 27:181.
35. Cossee M., Puccio H., Gansmuller A., et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000, 9:1219.
36. Whitnall M., Rahmanto Y.S., Sutak R., et al. The MCK mouse heart model of Friedreich's ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci USA 2008, 105:9757-9762.
37. Rayapureddi J.P., Tomamichel W.J., Walton S.T., Payne R.M. TAT fusion protein transduction into isolated mitochondria is accelerated by sodium channel inhibitors. Biochemistry 2010, 49:9470-9479.
38. Michael S., Petrocine S.V., Qian J., et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum (London, England) 2006, 5:257-267.
39. Al-Mahdawi S., Pinto R.M., Ismail O., et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 2008, 17:735-746.
40. Miranda C.J., Santos M.M., Ohshima K., et al. Frataxin knockin mouse. FEBS Lett 2002, 512:291.
41. Rai M., Soragni E., Jenssen K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008, 3:e1958.
42. Montermini L., Richter A., Morgan K., et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol 1997, 41:675-682.
43. Filla A., De Michele G., Cavalcanti F., et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996, 59:554-560.
44. Rajagopalan B., Francis J.M., Cooke F., et al. Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. Mov Disord 2010, 25:846-852.
45. Kipps A., Alexander M., Colan S.D., et al. The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood. Pediatr Cardiol 2009, 30:306-310.
46. Hanley A., Corrigan R., Mohammad S., MacMahon B. Friedreich's ataxia cardiomyopathy: case based discussion and management issues. Ir Med J 2010, 103:117-118.
47. Bunse M., Bit-Avragim N., Riefflin A., et al. Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia. Ann Neurol 2003, 53:121-123.
48. Rustin P., Rotig A., Munnich A., Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 2002, 36:467-469.
49. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., Di D.S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003, 60:1676.
50. Pineda M., Arpa J., Montero R., et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 2008, 12:470-475.
51. Velasco-Sanchez D., Aracil A., Montero R., et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum (London, England) 2011, 10:1-8.
52. Kearney M., Orrell R.W., Fahey M., Pandolfo M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev 2009, CD007791-818.
53. Lynch D.R., Perlman S.L., Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 2010, 67:941-947.
54. Hawley R.J., Gottdiener J.S. Five-year follow-up of Friedreich's ataxia cardiomyopathy. Arch Intern Med 1986, 146:483-488.
55. Palagi B., Picozzi R., Casazza F., et al. Biventricular function in Friedreich's ataxia: a radionuclide angiographic study. Br Heart J 1988, 59:692-695.
56. Dutka D.P., Donnelly J.E., Palka P., Lange A., Nunez D.J., Nihoyannopoulos P. Echocardiographic characterization of cardiomyopathy in Friedreich's ataxia with tissue Doppler echocardiographically derived myocardial velocity gradients. Circulation 2000, 102:1276-1282.
57. Hewer R. The heart in Friedreich's ataxia. Br Heart J 1969, 31:5-14.
58. Raman S.V., Phatak K., Hoyle J.C., et al. Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur Heart J 2011, 32:561-567.
59. Shaddy R.E., Boucek M.M., Hsu D.T., et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007, 298:1171-1179.
60. Richardson D.R. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin Investig Drugs 2003, 12:235-245.
61. Jauslin M.L., Meier T., Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003, 17:1972-1974.
62. Hart P.E., Lodi R., Rajagopalan B., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005, 62:621-626.
63. Boddaert N., Le Quan Sang K.H., Rotig A., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
64. Isaya G. Ironing out a therapy for Friedreich ataxia. Blood 2007, 110:1-2.
65. Watson M.S., Mann M.Y., Lloyd-Puryear M.A., Rinaldo P. Newborn screening: toward a uniform screening panel and system. Genet Med 2006, 8:1S-11S.
66. Del Gaizo Moore V., Payne R.M. Transactivator of transcription fusion protein transduction causes membrane inversion. J Biol Chem 2004, 279:32541-32544.
67. Del Gaizo-Moore V., MacKenzie J.A., Payne R.M. Targeting proteins to mitochondria using TAT. Mol Genet Metab 2003, 80:170.
68. Del Gaizo V., Payne R.M. A novel TAT-Mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 2003, 7:720.
69. Rapoport M., Saada A., Elpeleg O., Lorberboum-Galski H. TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther 2008, 16:691-697.
70. Gustafsson A.B., Sayen M.R., Williams S.D., Crow M.T., Gottlieb R.A. TAT protein transduction into isolated perfused hearts: TAT-apoptosis repressor with caspase recruitment domain is cardioprotective. Circulation 2002, 106:735-739.
71. Toro A., Grunebaum E. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest 2006, 116:2717-2726.